Aflibercept (Eylea — Bayer Inc.) indication: wet age-related macular degeneration
CADTH
Record ID 32015000167
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that aflibercept be listed for the treatment of neovascular (wet) age-related macular degeneration (AMD), if one condition is met.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0361-000_eylea_october_22_2014.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Angiogenesis Inhibitors
- Intravitreal Injections
- Treatment Outcome
- Vision Disorders
- Visual Acuity
- Wet Macular Degeneration
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.